MA46643A - Méthodes et compositions pour le mappage d'arn - Google Patents
Méthodes et compositions pour le mappage d'arnInfo
- Publication number
- MA46643A MA46643A MA046643A MA46643A MA46643A MA 46643 A MA46643 A MA 46643A MA 046643 A MA046643 A MA 046643A MA 46643 A MA46643 A MA 46643A MA 46643 A MA46643 A MA 46643A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- rna mapping
- rna
- mapping
- Prior art date
Links
- 238000013507 mapping Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412932P | 2016-10-26 | 2016-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46643A true MA46643A (fr) | 2019-09-04 |
Family
ID=62025494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046643A MA46643A (fr) | 2016-10-26 | 2017-10-26 | Méthodes et compositions pour le mappage d'arn |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20180274009A1 (fr) |
| EP (1) | EP3532613A4 (fr) |
| MA (1) | MA46643A (fr) |
| WO (1) | WO2018081462A1 (fr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| WO2017015463A2 (fr) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| US12150980B2 (en) | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| CA3002922A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccin contre le cytomegalovirus humain |
| EP3718565B1 (fr) | 2015-10-22 | 2022-04-27 | ModernaTX, Inc. | Vaccins contre le virus respiratoire |
| MA46080A (fr) | 2015-10-22 | 2019-07-10 | Modernatx Inc | Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv) |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| EP3364950A4 (fr) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Vaccins contre des maladies tropicales |
| JP7080172B2 (ja) | 2015-12-10 | 2022-06-03 | モデルナティエックス インコーポレイテッド | 治療薬の送達のための組成物及び方法 |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| WO2017201340A2 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucléotides codant la relaxine |
| ES2928475T3 (es) | 2016-09-14 | 2022-11-18 | Modernatx Inc | Composiciones de ARN de alta pureza y métodos para su preparación |
| WO2018075980A1 (fr) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
| EP3538146A4 (fr) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | Vaccin antigrippal |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP3582790A4 (fr) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | Compositions immunogènes très puissantes |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170260A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus respiratoire syncytial |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
| US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| EP3638215A4 (fr) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | Formulations d'arn |
| EP3668977A4 (fr) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | Procédés analytiques par hplc |
| MA49913A (fr) | 2017-08-18 | 2021-05-05 | Modernatx Inc | Variants d'arn polymérase |
| US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
| JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| US20200325532A1 (en) * | 2017-12-15 | 2020-10-15 | Novartis Ag | Polya tail length analysis of rna by mass spectrometry |
| EP3746090A4 (fr) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | Vaccins à base d'arn contre le vrs |
| JP7526168B2 (ja) | 2018-09-19 | 2024-07-31 | モデルナティエックス インコーポレイテッド | Ｐｅｇ脂質及びそれらの使用 |
| US12383508B2 (en) | 2018-09-19 | 2025-08-12 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| EP4010350A4 (fr) | 2019-08-09 | 2023-11-22 | Nutcracker Therapeutics, Inc. | Procédés et appareils de fabrication permettant d'éliminer un matériau d'une composition thérapeutique |
| US20220349006A1 (en) * | 2019-09-19 | 2022-11-03 | Moderna TX, Inc. | Cap guides and methods of use thereof for rna mapping |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| JP2024512780A (ja) * | 2021-04-01 | 2024-03-19 | モデルナティエックス インコーポレイテッド | 多価ｒｎａ組成物中のｒｎａ種の識別及び比率決定のための方法 |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4413153A1 (fr) * | 2021-10-08 | 2024-08-14 | Waters Technologies Corporation | Préparation d'échantillons pour la cartographie des séquences d'acides nucléiques basée sur la technique de chromatographie liquide-spectrométrie de masse |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12173368B2 (en) | 2022-03-11 | 2024-12-24 | New England Biolabs, Inc. | Compositions and analysis of dephosphorylated oligoribonucleotides |
| WO2024002985A1 (fr) | 2022-06-26 | 2024-01-04 | BioNTech SE | Vaccin contre le coronavirus |
| WO2024256674A1 (fr) * | 2023-06-14 | 2024-12-19 | Sanofi | Procédés d'identification ou de quantification simultanée de modifications de coiffage et de queue d'arn messager |
| US20250188440A1 (en) * | 2023-12-01 | 2025-06-12 | Recode Therapeutics, Inc. | Method for quantifying an amount of capped messenger rna |
| WO2025235739A1 (fr) * | 2024-05-08 | 2025-11-13 | Waters Technologies Corporation | Procédés de cartographie d'arn à couverture de séquence élevée |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539953A2 (fr) * | 2002-09-12 | 2005-06-15 | Nuevolution A/S | Synthese de molecules a matrice realisee par proximite |
| US8911948B2 (en) * | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US20160032273A1 (en) * | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| WO2017031241A1 (fr) * | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Cartographie/profilage de l'arn |
-
2017
- 2017-10-26 WO PCT/US2017/058591 patent/WO2018081462A1/fr not_active Ceased
- 2017-10-26 MA MA046643A patent/MA46643A/fr unknown
- 2017-10-26 EP EP17865334.1A patent/EP3532613A4/fr active Pending
-
2018
- 2018-06-06 US US16/001,765 patent/US20180274009A1/en not_active Abandoned
-
2022
- 2022-06-29 US US17/852,974 patent/US20230212645A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180274009A1 (en) | 2018-09-27 |
| EP3532613A4 (fr) | 2020-05-06 |
| EP3532613A1 (fr) | 2019-09-04 |
| US20230212645A1 (en) | 2023-07-06 |
| WO2018081462A1 (fr) | 2018-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3532613A4 (fr) | Méthodes et compositions pour le mappage d'arn | |
| EP3679141C0 (fr) | Méthodes et compositions pour inhiber l'expression de la ldha | |
| MA49421A (fr) | Formulations d'arn | |
| EP3707257A4 (fr) | Méthodes et compositions pour des molécules d'arn circulaire | |
| EP3353309A4 (fr) | Compositions et méthodes pour l'édition génomique | |
| EP3362104A4 (fr) | Méthodes et compositions utilisant cpf1 pour l'édition génétique guidée par l'arn | |
| MA49913A (fr) | Variants d'arn polymérase | |
| MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
| EP3324978A4 (fr) | Compositions d'oligonucléotides et méthodes associées | |
| EP3356529A4 (fr) | Compositions et méthodes permettant d'inhiber l'expression du gène de lpa | |
| EP3781705A4 (fr) | Compositions et méthodes pour l'édition génique | |
| EP3589646A4 (fr) | Compositions à base de cd19 et méthodes pour l'immunothérapie | |
| MA49403A (fr) | Compositions de pde5 et méthodes d'immunothérapie | |
| MA71468A (fr) | Compositions et méthodes pour diminuer l'expression de tau | |
| EP3445407A4 (fr) | Compositions et méthodes d'immunothérapie cellulaire | |
| EP3328377A4 (fr) | Compositions et méthodes pour thérapies immuno-oncologiques | |
| MA44479A (fr) | Arn transrepliquant | |
| EP3402549A4 (fr) | Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci | |
| EP3436083A4 (fr) | Nouvelles compositions et méthodes | |
| EP3291794A4 (fr) | Méthodes et compositions pour favoriser la pousse des cheveux | |
| EP3302588A4 (fr) | Compositions et méthodes pour l'adhérence à des surfaces | |
| EP3352800A4 (fr) | Méthodes et compositions pour réduire les métastases | |
| EP3402883A4 (fr) | Compositions et méthodes pour le séquençage d'acides nucléiques | |
| EP3380471A4 (fr) | Méthodes et compositions d'inhibition de comt | |
| MA54143A (fr) | Compositions et méthodes |